NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a co-marketing agreement with Long Island Pathology to promote MDxHealth's ConfirmMDx for Prostate Cancer test.

LI Path is an independent anatomic and clinical pathology lab serving the New York City metropolitan area, and MDxHealth expects the deal to expand its access to urologists in that market. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.